MicroRNAs in thyroid eye disease: expression signatures and clinical implications.

Area of Science:

• Ophthalmology
• Immunology
• Molecular Biology

Background:

• Thyroid eye disease (TED), also known as Graves' ophthalmopathy (GO), is an autoimmune orbital disorder.
• Immune dysregulation targeting self-antigens activates orbital fibroblasts, causing hyperplasia and fibrosis, leading to proptosis and eyelid retraction.
• MicroRNAs (miRNAs) are crucial post-transcriptional regulators implicated in TED development.

Purpose of the Study:

• To review the pathogenesis of thyroid eye disease.
• To discuss the emerging role of miRNAs in TED based on clinical and experimental evidence.
• To provide insights for future research and therapeutic strategies targeting miRNAs in TED.

Main Methods:

• Literature review of current clinical and experimental evidence on TED pathogenesis.
• Analysis of altered miRNA expression profiles (e.g., miR-21, miR-146a, miR-144-3p) in TED.
• Examination of miRNA involvement in fibroblast activation, fibrosis, adipogenesis, and inflammation in TED models.

Main Results:

• Specific miRNAs are differentially expressed in TED patients and in vitro models.
• These miRNAs are associated with key pathological processes in TED, including fibroblast activation and fibrosis.
• miRNAs are implicated in adipogenesis and inflammation within the orbit during TED.

Conclusions:

• MicroRNAs are significant players in the pathogenesis of thyroid eye disease.
• Altered miRNA expression highlights their potential as mechanistic targets for novel TED therapies.
• Further research into miRNA function could lead to innovative therapeutic developments for TED.